Literature DB >> 20198317

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects.

Lovisa Göstring1, Ming Tsuey Chew, Anna Orlova, Ingmarie Höidén-Guthenberg, Anders Wennborg, Jörgen Carlsson, Fredrik Y Frejd.   

Abstract

Tumor cell internalization of targeting agents is of interest, since internalization influences the local retention time of a radionuclide and thereby imaging quality in PET and SPECT and effects of radionuclide therapy. In cases where nuclear methods are not applicable at the cellular level, quantitative fluorescent techniques are useful as described in this article. Two fluorescence-based methods to study cellular internalization were applied: the CypHer and the Alexa488-quenching methods, both utilized in fluorescence microscopy and flow cytometry. Two EGFR-binding Affibody molecules were analyzed in A431 cells: the monomer Z1907 and the dimer (Z1907)2. EGF, cetuximab and non-specific Affibody molecules were used as controls. For comparison, internalization of 111In-labeled Z1907 was studied with the acid wash internalization assay. The Cypher method is straightforward, but requires equal labeling of all compounds for accurate quantification. The Alexa488-quenching method is preferable since it is independent of the dye-to-protein ratio. According to this method, about 45% of EGF and 19-24% of the bound Affibody molecules and cetuximab were internalized within one hour. Similar results were seen with 111In-Z1907 in the acid wash method, while (Z1907)2 was not removed by acid and thus could not be studied this way. The fluorescence-based Alexa488-quenching method is well suited to quantitatively analyze internalization of targeting agents, also those that resist acid wash. The internalized fraction showed that both the monomeric and dimeric Affibody molecules are expected to give good uptake and thereby good retention of metallic radionuclides which will render good tumor to background values.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198317     DOI: 10.3892/ijo_00000551

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

2.  A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics.

Authors:  Lin Qiu; Qingyu Lin; Zhan Si; Hui Tan; Guobing Liu; Jun Zhou; Tingting Wang; Yue Chen; Yingzhao Huang; Tao Yu; Mingzhi Jin; Dengfeng Cheng; Hongcheng Shi
Journal:  Mol Imaging Biol       Date:  2020-09-10       Impact factor: 3.488

3.  Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.

Authors:  Chao Zhang; Mengnan Han; Fanghua Zhang; Xueli Yang; Jie Du; Honglei Zhang; Wei Li; Shengxi Chen
Journal:  Int J Nanomedicine       Date:  2020-02-10

4.  Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration.

Authors:  Wei Liu; Daniel K Hsu; Huan-Yuan Chen; Ri-Yao Yang; Kermit L Carraway; Roslyn R Isseroff; Fu-Tong Liu
Journal:  J Invest Dermatol       Date:  2012-07-12       Impact factor: 8.551

5.  Heptameric targeting ligands against EGFR and HER2 with high stability and avidity.

Authors:  Dongwook Kim; Yitang Yan; C Alexander Valencia; Rihe Liu
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

6.  Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage.

Authors:  Edward R Smith; Eric Hanssen; Lawrence P McMahon; Stephen G Holt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

7.  Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.

Authors:  David W LaFleur; Donara Abramyan; Palanisamy Kanakaraj; Rodger G Smith; Rutul R Shah; Geping Wang; Xiao-Tao Yao; Spandana Kankanala; Ernie Boyd; Liubov Zaritskaya; Viktoriya Nam; Bridget A Puffer; Pete Buasen; Shashi Kaithamana; Andrew F Burnette; Rajesh Krishnamurthy; Dimki Patel; Viktor V Roschke; Peter A Kiener; David M Hilbert; Carlos F Barbas
Journal:  MAbs       Date:  2013 Mar-Apr       Impact factor: 5.857

8.  Fluorogen activating protein-affibody probes: modular, no-wash measurement of epidermal growth factor receptors.

Authors:  Yi Wang; Cheryl A Telmer; Brigitte F Schmidt; Josef D Franke; Stephan Ort; Donna J Arndt-Jovin; Marcel P Bruchez
Journal:  Bioconjug Chem       Date:  2014-12-19       Impact factor: 4.774

9.  Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals.

Authors:  Inna Vainshtein; Lorin K Roskos; Jackie Cheng; Matthew A Sleeman; Bing Wang; Meina Liang
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

10.  Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models.

Authors:  Outi Keinänen; Kimberly Fung; Jacob Pourat; Vilma Jallinoja; Delphine Vivier; NagaVara Kishore Pillarsetty; Anu J Airaksinen; Jason S Lewis; Brian M Zeglis; Mirkka Sarparanta
Journal:  EJNMMI Res       Date:  2017-12-02       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.